HUM Upgraded by Baird -- Price Target Raised to $596
Humana (HUM) was upgraded to Outperform from Neutral by Baird, with a price target raised from $390 to $596, indicating a 52.82% growth outlook. The stock is currently priced at $387.12, slightly overvalued according to its GF Value™ of $381.40. Humana has a GF Score™ of 83/100, reflecting strong performance in growth and profitability, but lower financial strength. 17 gurus hold HUM, with mixed activity in recent quarters.
How this was made
The 30-second read
Why it matters
The Baird upgrade could attract new buying, but valuation concerns may temper the rally.
Market read
Analyst upgrades are a common driver of short‑term price moves, especially with a sizable target increase.
What to watch
Potential headwinds from Medicare reimbursement pressures and high P/E multiple.
Background
Humana is a large U.S. health insurer with exposure to Medicare Advantage and Medicaid programs.
Ticker impact
Baird upgraded Humana to Outperform and raised the price target to $596, a fresh analyst recommendation.
likely upward pressure as investors price in the new target
The upgrade and 52.8% target increase provide a clear catalyst for buying interest.
Market effects
May lift sentiment for the broader healthcare insurance sector.
U.S. market focus, limited regional effect.
Modest, confined to U.S. equities.
Counterpoint
The upgrade may be premature given the stock's current overvaluation relative to its GF value.
Key entities
- companyHumana Inc.
U.S. health insurance provider.
- analyst_firmBaird
Equity research firm issuing the upgrade.
